Eicosanoids and Allograft Rejection
The relationship of fatty acids to immunity is of considerable interest (Meade and Mertin, 1978). Their role is now believed to be mediated by their oxidation products, specifically, the eicosanoids. The metabolites of arachidonic acid and drugs that affect their metabolism have far-reaching implications in organ transplantation. One of the major problems in evaluating the role of these eicosanoids is their remarkably diverse effects on many biological systems. The diversity of action appears to be receptor mediated, and receptor classification awaits the synthesis of specific eicosanoid antagonists. Diametrically opposite properties of individual metabolites are apparent in other fields and are well recognized, as is the case with the steroids. Here we are concerned with eicosanoids that are immuno-suppressive and others that clearly promote organ rejection.
KeywordsAllograft Rejection Cardiac Allograft Allograft Survival Daily Serum Cardiac Allograft Rejection
Unable to display preview. Download preview PDF.
- Foegh, M., Maddox, Y., Winchester, J., Rakowski, T., Schreiner, G., and Ramwell, P.W., 1983, Prostacyclin and thromboxane release from human peritoneal macrophages, Adv. Prostaglandin Thromboxane Leukotriene Res. 12:45–49.Google Scholar
- Foegh, M.L., Alijani, M.R., Helfrich, G.H., Khirabadi, B.S., Goldman, M.H., Lower, R.R., and Ramwell, P.W., 1985a, Thromboxane and leutrotrienes in clinical and experimental transplant rejection, Adv. Prostaglandin Thromboxane Leukotriene Res. 13:209–217.Google Scholar
- Foegh, M. L., Khirabadi, B., and Ramwell, P. W., 1985b, Prolongation of experimental cardiac allograft survival with thromboxane related drugs, Transplantation (in press).Google Scholar
- Hirata, F., Carmine, R., Nelson, C.A., Axelrod, J., Shiffman, E., Warabi, A., Bias, A., Nirenberg, M., Manganiello, V., Vaughan, M., Kumagai, S., Green, I., Decker, J., and Steinberg, A., 1981, Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic disease, Proc. Natl. Acad. Sci. U.S.A. 78:3190–3194.PubMedCrossRefGoogle Scholar
- Jamieson, S. W., Burton, N., and Reitz, B., 1979, Platelets, sulfinpyrazone and organ graft rejection, in: Cardiovascular Actions of Sulfinpyrazon: Basic and Clinical Research (M. McCregor, J. Mustard, M. Oliver, and S. Sherry, eds.), Symposia Specialist, Miami, pp. 229–243.Google Scholar
- Kort, W.J., Bonta, I.L., Adolfs, M.J.P., and Westbroek, D.L., 1982, Synergism of (15 5-15-methylprostaglandin E1 with either azathioprine or prednisolone on the survival of heart allografts in rats, Prostaglandins Leukotrienes Med. 8:661–664.Google Scholar
- Leithner, C.G., Sinzinger, H., Schwartz, M., Pohanka, E., and Syre, G.H., 1983, Increased deposition of indium-111 labelled platelets in chronically rejected kidney transplants, Clin. Nephrol. 18:311–313.Google Scholar
- Maddox, Y., Shapiro, R., Goldman, M., Lower, R., and Ramwell, P., 1984, Contractile effects of leukotriene C4 and the thromboxane mimic U46619 on human pulmonary arteries and veins in vitro, in: Clinically Related Lipids, Vol. 2 (T. J. Powles, R. S. Bochman, K. V. Honn, and P. Ramwell, eds.), Alan R. Liss, New York, pp. 47–65.Google Scholar
- Maddox, Y., Cunard, C, Shapiro, R. Mitchell, G., Lower, R., and Ramwell, P., 1985, A comparison of the contractile responses of rodent and human pulmonary vascular segments to icosanoids, in this volume.Google Scholar
- Mead, C.J., and Mertin, J., 1978, Fatty acids and immunity, Adv. Lipid Res. 16:127–65.Google Scholar
- Shaw, J. F. L., 1984, Drugs affecting the prostaglandin synthetic pathway and rat heart allograft survival, in: Platelets, Prostaglandins and Cardiovascular System, Abstract, Florence, p. 130.Google Scholar
- Sinzinger, H., Leithner, C, and Schwarz, M., 1981, Monitoring of human kidney transplants using quantification of autologous 111 indium-oxine platelet label deposition–beneficial effect of PGI2-treatment in acute (AR) and chronic (CR) rejection, Thomb. Haemostas. 46:263.Google Scholar